Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210397531> ?p ?o ?g. }
- W4210397531 endingPage "791" @default.
- W4210397531 startingPage "791" @default.
- W4210397531 abstract "Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed several categories of patient characteristics (age, renal function, DLBCL subtype, absolute lymphocyte count, transplant status, number of prior lines of therapy, refractory status, Ann Arbor disease stage, and lactate dehydrogenase) at baseline, i.e., during screening procedures, to determine their potential contributions to the efficacy (overall response rate [ORR], duration of response [DOR], overall survival [OS]) and tolerability of selinexor. Across most categories of characteristics, no significant difference was observed in ORR or DOR. OS was significantly longer for patients < 65 vs. ≥ 65 years, and for those with lymphocyte counts ≥ 1000/µL vs. < 1000/µL or lactate dehydrogenase ≤ ULN vs. > ULN. The most common adverse events (AEs) across the characteristics were thrombocytopenia and nausea, and similar rates of grade 3 AEs and serious AEs were observed. With its oral administration, novel mechanism of action, and consistency in responses in heavily pretreated patients, selinexor may help to address an important unmet clinical need in the treatment of DLBCL." @default.
- W4210397531 created "2022-02-08" @default.
- W4210397531 creator A5000530935 @default.
- W4210397531 creator A5005526796 @default.
- W4210397531 creator A5006235077 @default.
- W4210397531 creator A5008224705 @default.
- W4210397531 creator A5012590429 @default.
- W4210397531 creator A5014125875 @default.
- W4210397531 creator A5014153145 @default.
- W4210397531 creator A5016048836 @default.
- W4210397531 creator A5017301854 @default.
- W4210397531 creator A5017728103 @default.
- W4210397531 creator A5019711205 @default.
- W4210397531 creator A5021807846 @default.
- W4210397531 creator A5022817237 @default.
- W4210397531 creator A5024342638 @default.
- W4210397531 creator A5029569818 @default.
- W4210397531 creator A5029935496 @default.
- W4210397531 creator A5033073385 @default.
- W4210397531 creator A5036988600 @default.
- W4210397531 creator A5037546722 @default.
- W4210397531 creator A5051721992 @default.
- W4210397531 creator A5054416214 @default.
- W4210397531 creator A5057254430 @default.
- W4210397531 creator A5059591560 @default.
- W4210397531 creator A5062305482 @default.
- W4210397531 creator A5065546672 @default.
- W4210397531 creator A5068927620 @default.
- W4210397531 creator A5080068726 @default.
- W4210397531 creator A5081234421 @default.
- W4210397531 creator A5083191976 @default.
- W4210397531 creator A5083858828 @default.
- W4210397531 date "2022-02-04" @default.
- W4210397531 modified "2023-10-16" @default.
- W4210397531 title "The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study" @default.
- W4210397531 cites W1969906182 @default.
- W4210397531 cites W1987452803 @default.
- W4210397531 cites W2015798544 @default.
- W4210397531 cites W2048378034 @default.
- W4210397531 cites W2058015212 @default.
- W4210397531 cites W2060020125 @default.
- W4210397531 cites W2081023287 @default.
- W4210397531 cites W2115694405 @default.
- W4210397531 cites W2133812003 @default.
- W4210397531 cites W2160305510 @default.
- W4210397531 cites W2167571754 @default.
- W4210397531 cites W2169725967 @default.
- W4210397531 cites W2170055174 @default.
- W4210397531 cites W2492791618 @default.
- W4210397531 cites W2537020673 @default.
- W4210397531 cites W2587923824 @default.
- W4210397531 cites W2744261860 @default.
- W4210397531 cites W2794340145 @default.
- W4210397531 cites W2890442448 @default.
- W4210397531 cites W2980479610 @default.
- W4210397531 cites W3004671958 @default.
- W4210397531 cites W3037697670 @default.
- W4210397531 cites W3186039091 @default.
- W4210397531 doi "https://doi.org/10.3390/cancers14030791" @default.
- W4210397531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35159058" @default.
- W4210397531 hasPublicationYear "2022" @default.
- W4210397531 type Work @default.
- W4210397531 citedByCount "1" @default.
- W4210397531 countsByYear W42103975312023 @default.
- W4210397531 crossrefType "journal-article" @default.
- W4210397531 hasAuthorship W4210397531A5000530935 @default.
- W4210397531 hasAuthorship W4210397531A5005526796 @default.
- W4210397531 hasAuthorship W4210397531A5006235077 @default.
- W4210397531 hasAuthorship W4210397531A5008224705 @default.
- W4210397531 hasAuthorship W4210397531A5012590429 @default.
- W4210397531 hasAuthorship W4210397531A5014125875 @default.
- W4210397531 hasAuthorship W4210397531A5014153145 @default.
- W4210397531 hasAuthorship W4210397531A5016048836 @default.
- W4210397531 hasAuthorship W4210397531A5017301854 @default.
- W4210397531 hasAuthorship W4210397531A5017728103 @default.
- W4210397531 hasAuthorship W4210397531A5019711205 @default.
- W4210397531 hasAuthorship W4210397531A5021807846 @default.
- W4210397531 hasAuthorship W4210397531A5022817237 @default.
- W4210397531 hasAuthorship W4210397531A5024342638 @default.
- W4210397531 hasAuthorship W4210397531A5029569818 @default.
- W4210397531 hasAuthorship W4210397531A5029935496 @default.
- W4210397531 hasAuthorship W4210397531A5033073385 @default.
- W4210397531 hasAuthorship W4210397531A5036988600 @default.
- W4210397531 hasAuthorship W4210397531A5037546722 @default.
- W4210397531 hasAuthorship W4210397531A5051721992 @default.
- W4210397531 hasAuthorship W4210397531A5054416214 @default.
- W4210397531 hasAuthorship W4210397531A5057254430 @default.
- W4210397531 hasAuthorship W4210397531A5059591560 @default.
- W4210397531 hasAuthorship W4210397531A5062305482 @default.
- W4210397531 hasAuthorship W4210397531A5065546672 @default.
- W4210397531 hasAuthorship W4210397531A5068927620 @default.
- W4210397531 hasAuthorship W4210397531A5080068726 @default.
- W4210397531 hasAuthorship W4210397531A5081234421 @default.
- W4210397531 hasAuthorship W4210397531A5083191976 @default.
- W4210397531 hasAuthorship W4210397531A5083858828 @default.
- W4210397531 hasBestOaLocation W42103975311 @default.
- W4210397531 hasConcept C121332964 @default.
- W4210397531 hasConcept C126322002 @default.